Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
285 stopped studies mapped to Acute Lymphoblastic Leukemia and descendants · 88% state a reason
Over the 285 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04029038 | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or… | Phase 1 / Phase 2 | withdrawn | Jul 23, 2019 | M.D. Anderson Cancer Center | 0 participant accrual | Enrollment / accrual |
| NCT02134782 | Yoga Fatigue Study | N/A | terminated | May 9, 2014 | The Hospital for Sick Children | The study was closed early for poor accrual when 125/210 planned participants had been enrolled and… | Enrollment / accrual |
| NCT03229876 | Safety and Efficacy Evaluation of CD19-UCART | N/A | suspended | Jul 26, 2017 | Bioray Laboratories | Sponsor decision | Sponsor / business decision |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients… | Early Phase 1 | terminated | Sep 5, 2017 | Rutgers, The State University of New Jersey | Lack of enrollment | Enrollment / accrual |
| NCT02935543 | CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL | Phase 2 | terminated | Oct 17, 2016 | University of Pennsylvania | Study is terminated because of administrative reasons. | Other (stated, no rule matched) |
| NCT05037669 | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric… | Phase 1 | withdrawn | Sep 8, 2021 | University of Pennsylvania | No available investigational product | Other (stated, no rule matched) |
| NCT05645133 | QPlus Pediatric Reference Interval | — | terminated | Dec 9, 2022 | HemoSonics LLC | PI relocated to another institution | Other (stated, no rule matched) |
| NCT03705507 | International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of…(SeluDex) | Phase 1 / Phase 2 | terminated | Oct 15, 2018 | University of Birmingham | Poor recruitment, due to a change in the standard of care for this patient population with the use… | Enrollment / accrual |
| NCT03043430 | Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients | Phase 4 | terminated | Feb 6, 2017 | Brooke Army Medical Center | Research manpower shortage | Other (stated, no rule matched) |
| NCT05361356 | Spectral CT Clinical Trial | N/A | terminated | May 4, 2022 | Philips (China) Investment CO., LTD | Investigational product had been released in NMPA, Sponsor decided to terminate the study aligned… | Investigator |
| NCT04311866 | Femoral Pediatric Fractures. Walking Spica Cast vs Synthetic Pants | N/A | withdrawn | Mar 17, 2020 | Universidad Autonoma de Nuevo Leon | Lack of material for treatment of the patients | Other (stated, no rule matched) |
| NCT04156659 | Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or… | Phase 2 | withdrawn | Nov 7, 2019 | Novartis Pharmaceuticals | This study was cancelled before enrolling any patients for business related reasons. | Enrollment / accrual |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | Phase 1 | withdrawn | Aug 24, 2022 | Shanghai Pudong Hospital | The study is not initiated and we want it to be withdrawn. | Other (stated, no rule matched) |
| NCT00589316 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body… | Phase 1 | terminated | Jan 9, 2008 | Fred Hutchinson Cancer Center | Terminated due to loss of funding | Funding |
| NCT04095858 | Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease…(CATHY) | Phase 3 | terminated | Sep 19, 2019 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business Reasons | Sponsor / business decision |
| NCT04225676 | Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young… | Phase 2 | terminated | Jan 13, 2020 | Novartis Pharmaceuticals | Terminated due to slow enrollment | Enrollment / accrual |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT05168748 | CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia | Phase 1 | withdrawn | Dec 23, 2021 | Novartis Pharmaceuticals | Sponsor's decision | Sponsor / business decision |
| NCT04343027 | Patient Satisfaction in the Orthopedic Surgery Clinic | N/A | withdrawn | Apr 13, 2020 | NYU Langone Health | Withdrawn project - did not progress to enrollment. | Enrollment / accrual |
| NCT05571540 | Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | Phase 1 / Phase 2 | withdrawn | Oct 7, 2022 | Kunming Hope of Health Hospital | The PI decides to stop. | Other (stated, no rule matched) |
| NCT04860817 | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and… | Early Phase 1 | withdrawn | Apr 27, 2021 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | No proper participant is found. | Other (stated, no rule matched) |
| NCT05611086 | N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia | Phase 4 | terminated | Nov 9, 2022 | Teny Tjitra Sari | The study stopped because the study period already ended | Other (stated, no rule matched) |
| NCT03518112 | Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia… | Phase 2 | terminated | May 8, 2018 | M.D. Anderson Cancer Center | Due to Competing Studies | Other (stated, no rule matched) |
| NCT02618109 | Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute…(LABMI) | Phase 4 | terminated | Dec 1, 2015 | University Hospital, Angers | recruitment difficulties | Enrollment / accrual |
| NCT04282174 | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies(2019-KOE-001) | Phase 2 | withdrawn | Feb 24, 2020 | Baptist Health South Florida | Study was split into two new studies before the first participant was enrolled. | Enrollment / accrual |
| NCT01440179 | SAR3419 in Acute Lymphoblastic Leukemia(MYRALL) | Phase 2 | terminated | Sep 26, 2011 | Sanofi | The study is stopped due to very modest activity compared to competitors | Other (stated, no rule matched) |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
| NCT04807478 | Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis… | — | withdrawn | Mar 19, 2021 | Fresenius Kabi | New study protocol under development | Other (stated, no rule matched) |
| NCT03768310 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic… | Phase 1 | withdrawn | Dec 7, 2018 | Baylor College of Medicine | We decided to move on to another product and as a result will not be moving forward with this study. | Other (stated, no rule matched) |
| NCT00961142 | Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity…(CD3/CD19 Haplo) | Phase 2 | terminated | Aug 18, 2009 | University Hospital Tuebingen | slow recruitment | Enrollment / accrual |
| NCT02999854 | Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation…(HATCY) | Phase 3 | terminated | Dec 21, 2016 | Kiadis Pharma | Insufficient efficacy, terminated by Sponsor | Efficacy / futility |
| NCT04844086 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | Phase 1 | terminated | Apr 14, 2021 | Eden BioCell Ltd. | CAR-T manufacturing technology can not meet the dose requirement for clinical patients. | Drug supply |
| NCT02043587 | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic… | Phase 2 | terminated | Jan 23, 2014 | University of California, San Diego | Original investigator for the trial has left | Investigator |
| NCT00968864 | T-cell Depleted Alternative Donor Transplantation | Phase 2 | terminated | Aug 31, 2009 | Wake Forest University Health Sciences | Sponsor/ PI leaving institution, no plans to continue this research at this time | Other (stated, no rule matched) |
| NCT01187810 | Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | Phase 1 | terminated | Aug 24, 2010 | South Plains Oncology Consortium | drug supply | Drug supply |
| NCT03668392 | Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic…(ALL2518) | Phase 2 | terminated | Sep 12, 2018 | Gruppo Italiano Malattie EMatologiche dell'Adulto | low enrollment rate | Enrollment / accrual |
| NCT03696537 | IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT | Phase 1 | terminated | Oct 4, 2018 | Naoyuki G. Saito, M.D., Ph.D. | Extreme toxicity | Safety / toxicity |
| NCT04448834 | Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL | Phase 2 | withdrawn | Jun 26, 2020 | Dorothy Sipkins, MD, PhD | Study not moving forward | Other (stated, no rule matched) |
| NCT04044560 | Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant(OZM-097) | Phase 2 | terminated | Aug 5, 2019 | University of British Columbia | Slow enrolment, loss of funding | Enrollment / accrual |
| NCT03851081 | Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed… | Phase 1 / Phase 2 | withdrawn | Feb 22, 2019 | Roswell Park Cancer Institute | no accrual | Enrollment / accrual |
| NCT03519984 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With… | Phase 1 | terminated | May 9, 2018 | University of Southern California | Study drug supply issue | Drug supply |
| NCT02795520 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute… | Phase 1 / Phase 2 | terminated | Jun 10, 2016 | OncoTherapy Science, Inc. | slow patient accrual | Enrollment / accrual |
| NCT01620216 | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic… | Phase 2 | terminated | Jun 15, 2012 | OHSU Knight Cancer Institute | Unable to recruit enough eligible subjects | Enrollment / accrual |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem… | Phase 1 | withdrawn | Jul 9, 2020 | Medigene AG | Medigene transfered all rights to a new Sponsor | Other (stated, no rule matched) |
| NCT01439347 | A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With… | Phase 3 | terminated | Sep 23, 2011 | Spectrum Pharmaceuticals, Inc | Sponsor decision | Sponsor / business decision |
| NCT03742323 | REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | terminated | Nov 15, 2018 | PETHEMA Foundation | Because of low recruitment | Enrollment / accrual |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate… | Phase 2 | withdrawn | Jul 27, 2018 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host… | Phase 2 / Phase 3 | terminated | Aug 27, 2009 | Kiadis Pharma | not stated | Not stated |
| NCT03579888 | CD19-Specific T Cells Post AlloSCT | Phase 1 | terminated | Jul 9, 2018 | M.D. Anderson Cancer Center | Study halted prematurely | Other (stated, no rule matched) |
| NCT02669264 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute… | Phase 1 | terminated | Feb 1, 2016 | ADC Therapeutics S.A. | The study was early terminated prior to part 2 because of slow accrual. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 21, 2023source: clinicaltrials